Literature DB >> 26890862

A Micro/Nano Composite for Combination Treatment of Melanoma Lung Metastasis.

Yu Mi1, Chaofeng Mu1, Joy Wolfram1, Zaian Deng1, Tony Ye Hu1, Xuewu Liu1, Elvin Blanco1, Haifa Shen1,2, Mauro Ferrari1,3.   

Abstract

The successful treatment of malignant disease generally requires the use of multiple therapeutic agents that are coordinated in a spatiotemporal manner to enable synergy. Here, a porous silicon-based micro/nano composite (MNC) that is capable of simultaneously delivering chemotherapeutic agents and small interfering RNA (siRNA) to the lungs following intravenous injection is designed. The pores of the silicon microparticles are loaded with B-Raf proto-oncogene serine/threonine kinase (BRAF) siRNA-containing liposomes, while the surface is conjugated with docetaxel-encapsulated polymeric nanoparticles. The synergistic antitumor effect of the MNC is demonstrated in vitro in melanoma cells and in vivo using a mouse model for melanoma lung metastasis. The MNC displays superior therapeutic efficacy and increased accumulation in metastatic melanoma lesions in the lungs in comparison to combination therapy with liposomes and polymers. The results indicate that the MNC can be used as an effective delivery vehicle for simultaneous enrichment of multiple therapeutic agents in the lungs.
© 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  biomaterials; drug delivery; melanoma lung metastasis; polymeric materials; siRNA delivery; silicon microdisks

Mesh:

Substances:

Year:  2016        PMID: 26890862      PMCID: PMC4837059          DOI: 10.1002/adhm.201500910

Source DB:  PubMed          Journal:  Adv Healthc Mater        ISSN: 2192-2640            Impact factor:   9.933


  56 in total

1.  Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications.

Authors:  Ennio Tasciotti; Xuewu Liu; Rohan Bhavane; Kevin Plant; Ashley D Leonard; B Katherine Price; Mark Ming-Cheng Cheng; Paolo Decuzzi; James M Tour; Fredika Robertson; Mauro Ferrari
Journal:  Nat Nanotechnol       Date:  2008-03-02       Impact factor: 39.213

2.  The shape effect of mesoporous silica nanoparticles on biodistribution, clearance, and biocompatibility in vivo.

Authors:  Xinglu Huang; Linlin Li; Tianlong Liu; Nanjing Hao; Huiyu Liu; Dong Chen; Fangqiong Tang
Journal:  ACS Nano       Date:  2011-06-08       Impact factor: 15.881

3.  Colocalized delivery of rapamycin and paclitaxel to tumors enhances synergistic targeting of the PI3K/Akt/mTOR pathway.

Authors:  Elvin Blanco; Takafumi Sangai; Suhong Wu; Angela Hsiao; Guillermo U Ruiz-Esparza; Carlos A Gonzalez-Delgado; Francisca E Cara; Sergio Granados-Principal; Kurt W Evans; Argun Akcakanat; Ying Wang; Kim-Anh Do; Funda Meric-Bernstam; Mauro Ferrari
Journal:  Mol Ther       Date:  2014-02-26       Impact factor: 11.454

4.  DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma.

Authors:  A Gupta; S Love; A Schuh; M Shanyinde; J M Larkin; R Plummer; P D Nathan; S Danson; C H Ottensmeier; P Lorigan; L Collins; A Wise; R Asher; R Lisle; M R Middleton
Journal:  Ann Oncol       Date:  2014-02-24       Impact factor: 32.976

5.  Degradation and biocompatibility of multistage nanovectors in physiological systems.

Authors:  Jonathan O Martinez; Michael Evangelopoulos; Ciro Chiappini; Xuewu Liu; Mauro Ferrari; Ennio Tasciotti
Journal:  J Biomed Mater Res A       Date:  2013-11-16       Impact factor: 4.396

6.  Biodistribution, pharmacokinetics and microSPECT/CT imaging of 188Re-bMEDA-liposome in a C26 murine colon carcinoma solid tumor animal model.

Authors:  Ya-Jen Chang; Chih-Hsien Chang; Tsui-Jung Chang; Chia-Yu Yu; Liang-Cheng Chen; Meei-Lin Jan; Tsai-Yueh Luo; Te-Wei Lee; Gann Ting
Journal:  Anticancer Res       Date:  2007 Jul-Aug       Impact factor: 2.480

Review 7.  Nanocarriers as an emerging platform for cancer therapy.

Authors:  Dan Peer; Jeffrey M Karp; Seungpyo Hong; Omid C Farokhzad; Rimona Margalit; Robert Langer
Journal:  Nat Nanotechnol       Date:  2007-12       Impact factor: 39.213

Review 8.  Multifunctional nanoparticles for drug delivery and molecular imaging.

Authors:  Gang Bao; Samir Mitragotri; Sheng Tong
Journal:  Annu Rev Biomed Eng       Date:  2013-04-29       Impact factor: 9.590

9.  COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.

Authors:  Cory M Johannessen; Jesse S Boehm; So Young Kim; Sapana R Thomas; Leslie Wardwell; Laura A Johnson; Caroline M Emery; Nicolas Stransky; Alexandria P Cogdill; Jordi Barretina; Giordano Caponigro; Haley Hieronymus; Ryan R Murray; Kourosh Salehi-Ashtiani; David E Hill; Marc Vidal; Jean J Zhao; Xiaoping Yang; Ozan Alkan; Sungjoon Kim; Jennifer L Harris; Christopher J Wilson; Vic E Myer; Peter M Finan; David E Root; Thomas M Roberts; Todd Golub; Keith T Flaherty; Reinhard Dummer; Barbara L Weber; William R Sellers; Robert Schlegel; Jennifer A Wargo; William C Hahn; Levi A Garraway
Journal:  Nature       Date:  2010-11-24       Impact factor: 49.962

10.  In vivo evaluation of the biodistribution and safety of PLGA nanoparticles as drug delivery systems.

Authors:  Boitumelo Semete; Laetitia Booysen; Yolandy Lemmer; Lonji Kalombo; Lebogang Katata; Jan Verschoor; Hulda S Swai
Journal:  Nanomedicine       Date:  2010-03-15       Impact factor: 5.307

View more
  14 in total

1.  A pyruvate decarboxylase-mediated therapeutic strategy for mimicking yeast metabolism in cancer cells.

Authors:  Bronwyn Scott; Jianliang Shen; Sara Nizzero; Kathryn Boom; Stefano Persano; Yu Mi; Xuewu Liu; Yuliang Zhao; Elvin Blanco; Haifa Shen; Mauro Ferrari; Joy Wolfram
Journal:  Pharmacol Res       Date:  2016-07-06       Impact factor: 7.658

2.  Clinical Cancer Nanomedicine.

Authors:  Joy Wolfram; Mauro Ferrari
Journal:  Nano Today       Date:  2019-03-06       Impact factor: 20.722

Review 3.  Melanoma treatment: from conventional to nanotechnology.

Authors:  Harshita Mishra; Pawan K Mishra; Adam Ekielski; Manu Jaggi; Zeenat Iqbal; Sushama Talegaonkar
Journal:  J Cancer Res Clin Oncol       Date:  2018-08-09       Impact factor: 4.553

Review 4.  Organotropic drug delivery: Synthetic nanoparticles and extracellular vesicles.

Authors:  Sara Busatto; Anthony Pham; Annie Suh; Shane Shapiro; Joy Wolfram
Journal:  Biomed Microdevices       Date:  2019-04-15       Impact factor: 2.838

5.  In Vivo Delivery and Therapeutic Effects of a MicroRNA on Colorectal Liver Metastases.

Authors:  Go Oshima; Nining Guo; Chunbai He; Melinda E Stack; Christopher Poon; Abhineet Uppal; Sean C Wightman; Akash Parekh; Kinga B Skowron; Mitchell C Posner; Wenbin Lin; Nikolai N Khodarev; Ralph R Weichselbaum
Journal:  Mol Ther       Date:  2017-04-28       Impact factor: 11.454

Review 6.  The Daniel K. Inouye College of Pharmacy Scripts: Targeted Nanocarrier Based Systems for the Treatment of Lung Cancer.

Authors:  Susanne R Youngren-Ortiz; Mahavir B Chougule
Journal:  Hawaii J Med Public Health       Date:  2017-11

7.  Enzyme-responsive multistage vector for drug delivery to tumor tissue.

Authors:  Yu Mi; Joy Wolfram; Chaofeng Mu; Xuewu Liu; Elvin Blanco; Haifa Shen; Mauro Ferrari
Journal:  Pharmacol Res       Date:  2016-08-19       Impact factor: 7.658

8.  Post-nano strategies for drug delivery: Multistage porous silicon microvectors.

Authors:  Alessandro Venuta; Joy Wolfram; Haifa Shen; Mauro Ferrari
Journal:  J Mater Chem B       Date:  2016-11-26       Impact factor: 6.331

9.  Extracellular vesicle therapeutics from plasma and adipose tissue.

Authors:  Dalila Iannotta; Man Yang; Christian Celia; Luisa Di Marzio; Joy Wolfram
Journal:  Nano Today       Date:  2021-04-27       Impact factor: 18.962

Review 10.  Engineering functional inorganic-organic hybrid systems: advances in siRNA therapeutics.

Authors:  Jianliang Shen; Wei Zhang; Ruogu Qi; Zong-Wan Mao; Haifa Shen
Journal:  Chem Soc Rev       Date:  2018-02-08       Impact factor: 60.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.